Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Relmada Therapeutics, Inc. (RLMD) had Weighted-Average Shares Outstanding (Diluted) of 30.16M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-79.98M |
|
-- |
|
-- |
|
$83.89M |
|
$-83.89M |
|
$3.91M |
|
$-79.98M |
|
$-80.36M |
|
$-79.98M |
|
$-79.98M |
|
$-79.98M |
|
$-80.36M |
|
$-83.89M |
|
$-83.89M |
|
30.16M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
30.16M |
$-2.65 |
|
$-2.65 |
|
| Balance Sheet Financials | |
$45.80M |
|
-- |
|
$0.02M |
|
$45.82M |
|
$10.29M |
|
-- |
|
$0.00M |
|
$10.30M |
|
$35.52M |
|
$35.52M |
|
$35.52M |
|
30.17M |
|
| Cash Flow Statement Financials | |
$-51.76M |
|
$51.56M |
|
$-0.04M |
|
$4.09M |
|
$3.86M |
|
$-0.23M |
|
$30.18M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.45 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-51.76M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-225.15% |
|
-225.15% |
|
-174.56% |
|
-225.15% |
|
$1.18 |
|
$-1.72 |
|
$-1.72 |
|